Prognostic Value of Inflammatory and Nutritional Markers for Patients With Early-Stage Poorly-to Moderately-Differentiated Cervical Squamous Cell Carcinoma
Background
The neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), systemic immune-inflammatory index (SII), systemic inflammation response index (SIRI), and Onodera’s prognostic nutritional index (OPNI) have been reported as prognostic markers for various cancers. We evaluated the prognostic value of the NLR, PLR, MLR, SII, SIRI, and OPNI for poorly-to moderately-differentiated cervical squamous cell carcinoma (CSCC).
Patients and Methods
We retrospectively analyzed the cases of 109 patients with early-stage poorly-to moderately-differentiated CSCC who underwent radical surgery at our institution in 2014-2017. The optimal cutoff points for the NLR, PLR, MLR, SII, SIRI, and OPNI were determined by receiver operating characteristic curves. Overall survival was analyzed by the Kaplan-Meier method. We performed a multivariate analysis using the Cox proportional hazard regression model to determine the independent prognostic indicators for early-stage poorly-to moderately-differentiated CSCC.
Results
The appropriate cutoff points were: NLR, 1.72; PLR, 111.96; MLR, .24; SII, 566.23; SIRI, 1.38; and OPNI, 52.68. The OS of the patients with a high OPNI ( P = .04), low SII ( P = .03), or low SIRI ( P = .01) was significantly better. The uni- and multivariate analyses identified only the OPNI as an independent prognostic marker for early-stage poorly-to moderately-differentiated CSCC ( P = .04 and P = .02).
Conclusion
The OPNI is an independent prognostic marker for early-stage poorly-to moderately-differentiated CSCC; the NLR, PLR, MLR, SII, and SIRI are not.
Top-30
Journals
|
1
2
|
|
|
Cancers
2 publications, 14.29%
|
|
|
Scientific Reports
2 publications, 14.29%
|
|
|
Annals of Medicine
1 publication, 7.14%
|
|
|
European Journal of Surgical Oncology
1 publication, 7.14%
|
|
|
Cureus
1 publication, 7.14%
|
|
|
Experimental and Therapeutic Medicine
1 publication, 7.14%
|
|
|
Gynecologic Oncology
1 publication, 7.14%
|
|
|
Frontiers in Oncology
1 publication, 7.14%
|
|
|
World Journal of Surgical Oncology
1 publication, 7.14%
|
|
|
Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology
1 publication, 7.14%
|
|
|
Future Science OA
1 publication, 7.14%
|
|
|
Frontiers in Immunology
1 publication, 7.14%
|
|
|
1
2
|
Publishers
|
1
2
3
4
|
|
|
Springer Nature
4 publications, 28.57%
|
|
|
Elsevier
3 publications, 21.43%
|
|
|
Taylor & Francis
2 publications, 14.29%
|
|
|
MDPI
2 publications, 14.29%
|
|
|
Frontiers Media S.A.
2 publications, 14.29%
|
|
|
Spandidos Publications
1 publication, 7.14%
|
|
|
1
2
3
4
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.